Artivion Amends Agreements with Endospan
Provided By PR Newswire
Last update: Jul 1, 2024
Provides Endospan with $25 million of Additional Debt Funding to Obtain FDA Approval for NEXUS
Upfront Payment Associated with Purchase Option Reduced to $135 million, inclusive of loan off-set, and $100 million earnout minimum eliminated
Read more at prnewswire.com
